BioAtla holds KOL event on BA3011 Phase 2 NSCLC data; no specific results given

BioAtla, Inc.

KOL event on Dec 4 featured Dr. Carl M. Gay (MD Anderson) discussing BA3011 (CAB-AXL-ADC) Phase 2 data in refractory NSCLC.
Select slides from the presentation filed as Exhibit 99.1; no detailed efficacy or safety numbers provided in the filing.
Company reiterates forward-looking statements; no guidance or material changes announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.